| 产品描述: | S65487 (VOB560), a potent and selective BCL-2 inhibitor, is a proagent of S55746. S65487 is also active on BCL-2 mutations, such as G101V and D103Y. S65487 has poor affinity with MCL-1, BFL-1 and BCL-XL. S65487 induces apoptosis and has anticaner activities[1][2]. |
| 体外研究: |
在单次 IV (静脉内) 给药后,S65487 在体内诱导 BCL-2 依赖性 RS4;11 肿瘤的完全消退。在每周静脉注射 S65487 和 MCL-1 特异性抑制剂 S64315/MIK665 后,在小鼠和大鼠淋巴恶性肿瘤异种移植模型中观察到强烈和持续的肿瘤消退[1]。 |
| 体内研究: |
在单次 IV (静脉内) 给药后,S65487 在体内诱导 BCL-2 依赖性 RS4;11 肿瘤的完全消退。在每周静脉注射 S65487 和 MCL-1 特异性抑制剂 S64315/MIK665 后,在小鼠和大鼠淋巴恶性肿瘤异种移植模型中观察到强烈和持续的肿瘤消退。 |
| 参考文献: |
1. Arnaud Le Tiran, et al. Abstract 1276: Identification of S65487/VOB560 as a potent and selective intravenous 2nd-generation BCL-2 inhibitor active in wild-type and clinical mutants resistant to Venetoclax. Cancer Research. July 2021. 2. American Association for Cancer Research, AACR. 2021.4.10-15. |
| 保存条件: |
-80°C 12个月; -20°C 6个月, 干燥 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.394 ml |
6.971 ml |
13.942 ml |
| 5 mM |
0.279 ml |
1.394 ml |
2.788 ml |
| 10 mM |
0.139 ml |
0.697 ml |
1.394 ml |
| 50 mM |
0.028 ml |
0.139 ml |
0.279 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |